Venture Capital Funding

AstronauTx biotech closes £48m Series A for Alzheimer’s drugs

London-based biotech developing drugs to cure Alzheimer’s, a disease which affects 55m people a year and costs the economy tens of billions


Deals of the Week Oct 17 to Oct 21 – a Growth Business round-up

Deals this week include an environmentally friendly rocket, animal fat created in bioreactors and a start-up looking to fuel planes with agricultural waste


Deals of the Week 16 May to 20 May – a Growth Business round-up

Deals this week include a platform for booking creatives, a biotech spinout and a wearable that warns of hazards in the workplace


Deals of the Week 18 April to 22 April – a Growth Business round-up

A crypto asset platform, a clinical service start-up and school facility hire service are all part of this week’s Deals of the Week


12 of the most exciting tech companies in Oxford

Oxford has become a top-notch digital hub, offering much to tech companies by capitalising on its long tradition of world-class innovation

Venture Capital Funding

Venture capital biotech funding increases 35% year on year

Venture capital channels over £2m a day into biotech, accounting for two thirds of all biotech funding


Number of biotechnology companies grows by two thirds over three years

Biotech business population flourishes since 2016 as annual investment reaches £2.2bn in 2018

Venture Capital Funding

Property tycoon to invest another $100m in tech companies

Vincent Tchenguiz has already invested $200m in VC funding, mainly in biotech.

PR and Marketing Strategy

Pharma and biotech: Are you marketing your products in the right way?

Knowing how to market a product or service isn't always something that comes naturally but is a pivotal part of your business.


NVM PE invests £3.5 million to combine leading cleantech firms

Cleveland Biotech and Biological Preparations beneficiaries of funding boost.


New investors added by Green Biologics through £15.4 million round

Green Biologics has now raised over £28 million of venture capital investment following an eight-figure Series B round.


Biofortuna secures more venture capital cash to ramp up US efforts

Molecular diagnostics business Biofortuna has closed another round of venture capital funding so that it can target the US market.